

02.16.00

A1
BOX SEQ

Express Mail No. EL401195882US

Docket No. 20347/111656

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Heinrich BACHMANN, et al.

Serial No.: Unassigned

Filed: Herewith

For: β , β -CAROTENE 15,15'-DIOXYGENASES, NUCLEIC ACID
SEQUENCES CODING THEREFOR AND THEIR USE

Examiner: Unassigned

Art Unit: Unassigned

JCE78 U.S. PTO
09/504393
02/15/00Box Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith for filing is the utility patent application of Inventors:

**Heinrich BACHMANN, Roland BRUGGER,
Arno Martin FRIEDLEIN, Gabriele Margarethe WIRTZ,
Wolf-Dietrich WOGGON, Adrian WYSS and Markus WYSS**

For:

1. [x] The application has 30 pages (including specification, claim pages, and abstract).
2. [x] 12 sheets of drawings are enclosed. The drawings are:
 - a. [x] formal; or
 - b. [] informal; formal drawings will be submitted in due course.
3. [x] A Sequence Listing is part of this continuing application.
 - a. [x] A Sequence Listing in both paper and computer readable form (diskette) as required by 37 CFR 1.821 et seq. is enclosed.
 - b. [x] A statement that the content of the paper and computer readable Sequence Listing are the same and that no new matter has been added is enclosed, pursuant to 37 CFR §1.821(f).
4. [x] The declaration and power of attorney
 - a. [] has been executed by all the inventors; or

- b. ☒ has not been executed by all the inventors. A signed declaration and power of attorney will be submitted in due course.
5. ☐ An associate power of attorney is enclosed.
6. ☐ An assignment of the invention from the Inventor(s) to F. Hoffmann-La Roche AG (with Recordation Form Cover Sheet in duplicate), and an assignment from F. Hoffmann-La Roche AG to Roche Vitamins Inc. (with Recordation Form Cover Sheet in duplicate) are enclosed. Please record the Assignment from the Inventor(s) to F. Hoffmann-La Roche AG first, then record the assignment from F. Hoffmann-La Roche AG to Roche Vitamins Inc., and return both to the undersigned. A duplicate copy of this paper is enclosed.
- a. ☐ Two checks in the amount of \$40 each are enclosed to cover the recording fees.
- b. ☐ Please charge the recording fee to our Deposit Account No. 02-4467. A duplicate copy of this paper is enclosed.
7. ☒ Priority is hereby claimed under 35 USC §119 based on Appln. No. **99103382.0**, filed **February 22, 1999** in **Europe**.
- a. ☒ A certified copy of the priority document is enclosed.
- b. ☐ The certified priority document will follow.
8. ☐ Priority is hereby claimed under 35 USC §119(e) based on provisional application Serial No. _____, filed _____, in _____. Please amend the specification by inserting, before the first line, the following sentence: -- This application claims priority under 35 U.S.C. § 119(e) of provisional application Serial No _____, filed _____. --
9. ☒ The filing fee is calculated below on the basis of the claims existing in the prior application plus or minus any claims added or canceled by amendment:

Claims as Filed, Plus/Minus Any Claims Added/Canceled By Amendment

For	Number Filed	Number Extra	Rate	Basic Fee = \$	690.00
Total claims	35 -20=	15	x \$18 =	\$	270.00
Independent claims	7 -3=	4	x \$78 =	\$	312.00
Total Filing Fees				\$	1,272.00

- a. ☒ A check in the amount of **\$1,272.00** to cover the filing fee is enclosed. If our check is missing or otherwise insufficient, or if any additional fees are required, please charge (or credit any overpayment) to Deposit Account No. 02-4467. A duplicate copy of this paper is enclosed.

- b. ☐ Please charge Deposit Account No. 02-4467 in the amount of \$ _____.
A duplicate copy of this paper is enclosed.
10. ☒ The Commissioner is hereby authorized to charge payment of the following fees, or to credit any overpayment, to Deposit Account No. 02-4467. A duplicate copy of this paper is enclosed.
- a. ☒ Any additional filing fees required under 37 CFR Section 1.16 not otherwise paid by check.
- b. ☒ Any patent application processing fees required under 37 CFR Section 1.17 not otherwise paid by check.
- c. ☒ Any additional Assignment recording fees under 37 CFR Section 1.21 (h) not otherwise paid by check.
11. ☐ A preliminary amendment is enclosed. Please enter it before calculating the filing fee.
12. ☐ An Information Disclosure Statement is enclosed.
13. ☒ Address all communications to:
- Mark E. Waddell, Esq.
Bryan Cave, LLP
245 Park Avenue
New York, NY 10167-0034
tel. (212) 692-1800

Respectfully submitted,

By: 

Kevin C. Hooper
Registration No. 40,402
BRYAN CAVE LLP
245 Park Avenue
New York, NY 10167-0034
(212) 692-1800

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of :)
Heinrich BACHMANN, et al.) Examiner: Unassigned
Serial No.: Unassigned) Art Unit: Unassigned
Filed: Herewith)
For: **β , β -CAROTENE 15,15'-DIOXYGENASES, NUCLEIC ACID
SEQUENCES CODING THEREFOR AND THEIR USE**

CERTIFICATE OF EXPRESS MAILING

"Express Mail" Mailing Label No.: EL401195882US

Date of Deposit: February 15, 2000

I hereby certify that the following:

- ☒ Certificate of Express Mailing
- ☒ Transmittal letter (3 pp, in duplicate)
- ☒ Specification, Claims and Abstract (30 pp)
- ☒ Twelve (12) Sheets of Formal Drawings
- ☒ Sequence Listing (11 pp)
- ☒ Computer Readable Sequence Listing (Diskette)
- ☒ Statement Under 37 CFR § 1.821 or § 1.825 (2 pp)
- ☒ Declaration and Power of Attorney (unexecuted) (4 pp)
- ☒ Certified Priority Document EP 99103382.0
- ☒ Check in the amount of \$1,272.00 (Filing fee)
- ☒ Return postcard

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR Section 1.10 on the Date of Deposit indicated above in an envelope addressed to the Assistant Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.


Eric Morales

Signature of Person Making Deposit

BRYAN CAVE LLP
245 Park Avenue
New York, New York 10167-0034
212/692-1800

**β, β-CAROTENE 15,15'-DIOXYGENASES, NUCLEIC
ACID SEQUENCES CODING THEREFOR AND THEIR USE**

FIELD OF THE INVENTION

The present invention concerns the cloning of β,β-carotene 15,15'-dioxygenase (EC 1.13.11.21), the enzyme responsible for the cleavage of β-carotene leading to vitamin A. The term vitamin A as defined in the present invention comprises a class of compounds including retinal, retinol, 3-dehydroretinol, retinoic acid, the isomers from these compounds as well as retinylesters. Proteins having β,β-carotene 15,15'-dioxygenase activity and nucleic acid sequences coding therefore can be used in different fields including but not limited to diagnostics, the technical production of vitamin A, the generation of transgenic plants in order to produce vitamin A in fruits and vegetables, or gene therapy.

SUMMARY OF THE INVENTION

In one embodiment of the present invention, a polypeptide having β,β-carotene 15,15'-dioxygenase activity is provided. This polypeptide includes SEQ ID NO: 1 or a polypeptide having β,β-carotene 15,15'-dioxygenase activity and being at least 60% homologous to SEQ ID NO: 1 as determined by the Wisconsin Sequence Analysis Package GCG, Version 9.1 (1997).

The present invention also includes a nucleic acid sequence encoding the polypeptide defined above, such as for example, SEQ ID NO: 2 or a fragment thereof.

Another embodiment of the invention is a primer for amplifying a gene coding for a protein having β , β -carotene 15,15'-dioxygenase activity which includes a nucleic acid sequence as defined above.

5 A probe is also provided for detecting a gene coding for a protein having β , β -carotene 15,15'-dioxygenase activity. This probe includes a nucleic acid sequence as defined above.

10 A test kit is also provided for amplifying and/or detecting a gene or a fragment thereof coding for β , β -carotene 15,15'-dioxygenase. The test kit includes at least one primer as defined above. The test kit may also include at least one probe as defined above alone, or in combination with at least one primer according to the present invention.

15 Another embodiment of the invention is an antibody which specifically reacts with a polypeptide as defined above.

20 An immunoassay is also provided for the detection and/or quantification of β , β -carotene 15,15'-dioxygenase. This immunoassay includes at least one antibody as set forth above.

A process is also provided for the production of vitamin A. This process includes enzymatically cleaving β -carotene by a polypeptide as described above.

25 Another embodiment is a method for introducing a β , β -carotene 15,15'-dioxygenase cDNA into a host cell. This method includes inserting a cDNA coding for a polypeptide as described above into a vector suitable for the host cell and introducing the vector into the host cell.

A host cell is also provided. This host cell may be obtained by the method set forth above. The host cell includes a β,β -carotene 15,15'-dioxygenase cDNA obtained from another species.

Another embodiment of the invention is a polynucleotide which encodes β,β -carotene 15,15'-dioxygenase and includes the sequence of SEQ ID NO: 2.

A vector is also provided which includes the sequence of SEQ ID NO: 2. A host cell is also provided which has been transformed with this vector.

The present invention also includes a polypeptide having β,β -carotene 15,15'-dioxygenase activity, which polypeptide contains the amino acid sequences of SEQ ID Nos: 1 or 4.

A primer set is also provided for amplifying a polynucleotide encoding β,β -carotene 15,15'-dioxygenase. This primer set includes SEQ ID NO: 8 as a 5' primer and a SEQ ID NO: 9 as a 3' primer. Another primer set for amplifying a polynucleotide encoding β,β -carotene 15,15'-dioxygenase is also provided which includes a polyT/Not reverse primer and SEQ ID NO:10 as a forward primer.

The present invention also includes a kit for amplifying and/or detecting a polypeptide or fragment thereof encoding β,β -carotene 15,15'-dioxygenase. This kit includes at least one primer selected from SEQ ID Nos: 8, 9, and 10.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the result from the last step of purification of β,β -carotene 15,15'-dioxygenase from the small intestine of chicken. The SDS-PAGE pattern and β,β -carotene 15,15'-dioxygenase activity of individual fractions from the gel permeation

chromatography run are shown. On the gel, the protein A marked by an arrow correlated

best with the β,β -carotene 15,15'-dioxygenase activity. It was therefore chosen for further amino acid sequence analysis. The abbreviations have the following meaning: Std.: molecular weight standard; conc.: concentrate loaded onto the gel permeation chromatography column.


Figure 2 shows schematically the transactivation assay in eukaryotic cells. cDNAs are transfected and expressed in MCF-7 cells. When incubated with β -carotene, a positive pool shows cleavage activity. The cleavage product retinal is further oxidized to retinoic acid (RA) which binds to the endogenous receptor. The receptor/ligand complex binds to the response element on the reporter plasmid and leads to an enhanced transcription of the luciferase gene. The luminescence signals are detected in a luciferase assay with a sensitive CCD camera.

Figure 3 shows the cDNA sequence (SEQ ID NO: 2) for β,β -carotene 15,15'-dioxygenase which has a length of 3090 base pairs excluding the poly A tail. 132 base pairs are 5' nontranslating sequence, the coding sequence has 1578 base pairs and the 3' nontranslating sequence 1380 base pairs, respectively. A putative poly A signal is found at position 3073.

Figure 4 shows the derived amino acid sequence (sequence ID No. 1) of β,β -carotene 15,15'-dioxygenase derived from chicken having 526 residues. The amino acid sequence is given in the one letter code.

Figure 5 shows a comparison of the β,β -carotene 15,15'-dioxygenase amino acid sequence (SEQ ID NO: 4) with a protein having the designation RPE65 (SEQ ID NO: 5) which was found by a sequence comparison in EMBL Genbank as the protein having the highest homology to the β,β -carotene 15,15'-dioxygenase of the present invention.

Scheme II:



Highest known enzymatic activity is found in the intestine of herbivores, especially in duodenum. In other tissues like liver, lung, kidney and brain β , β -carotene 15,15'-dioxxygenase is also detectable. Starting in 1955, many attempts have been undertaken to purify and characterize the enzyme by biochemical methods (Goodman (1965 and 1966), Fidge (1969), Laksmanan (1972), Sharma (1977) and Devery & Milborrow (British Journal of Nutrition (1994) 72, p. 397-414). However, none of these attempts has been successful. Specific activities of 600 pmol retinal formed/mg protein per hour have not been surpassed.

In the course of the present invention it was possible to purify the chicken enzyme to such a degree that a partial amino acid sequence could be obtained. The enzyme was enriched 226-fold, yielding a specific activity of 2500 pmol/h/mg. On a polyacrylamide gel of fractions from the final gel filtration run 15 bands were visible after Coomassie blue staining. Two bands correlated with the enzymatic activity profile of the β , β -carotene 15, 15'-dioxxygenase. With the first protein Edman sequencing and with the second MS spectroscopy was performed. Tryptic ingel digestion and subsequent microbore RP-HPLC peptide mapping in combination with MALDI-TOF MS and automated Edman degradation of this latter protein revealed 2 peptides of 11 and 18 amino acids. From this sequence information degenerate PCR primers were designed and synthesized.

With a PCR protocol a 51 bp (base pair) fragment was amplified within the longer peptide. From this sequence a homologous primer was synthesized and used in a second RT-PCR (reverse transcriptase - PCR) to amplify a 597 bp fragment.

5 This cDNA fragment was radioactively labeled and used for the screening of two positive pools from a chicken expression library in order to isolate the full length cDNA coding for β,β -carotene 15,15'-dioxygenase.

10 The positive pools were obtained from a cDNA library from chicken duodenum which was screened for β,β -carotene 15,15'-dioxygenase activity in a cellular transactivation assay. By this strategy several positive cDNA pools were identified. By combining the two strategies the gene coding for β,β -carotene 15,15'-dioxygenase could be successfully cloned.

15 It is an object of the present invention to provide a protein having the vitamin A producing activity of β,β -carotene 15,15'-dioxygenase comprising an amino acid sequence which is identical or homologous to SEQ ID NO: 1 (shown in Fig. 4) whereby the degree of homology to SEQ ID NO: 1 is at least 60%.

20 With the sequence of β,β -carotene 15,15'-dioxygenase isolated from chicken, corresponding proteins from different animals like swine, cow, goat, dog, rabbit, poultry, fish and humans can easily be obtained. Since the chicken sequence is known, suitable regions of the nucleic acid sequence can be selected as primers for a polymerase chain reaction with a suitable nucleic acid which allows an easy and rapid amplification of the
25 gene coding for the protein.

The present invention includes therefore not only proteins having an amino acid sequence identical to the sequence given in SEQ ID NO: 1 but also such proteins which have an amino acid sequence homologous to the SEQ ID NO: 1. The degree of homology
30 is, however, at least 60%, preferably 70%, more preferably 80%, such as for example, at

least 90%. Homology as defined in the present invention means that when the amino acid sequences of two proteins are aligned at least the given percentage is identical. The alignment of the amino acids is performed with the help of a suitable computer program which is commercially available, in particular, the Wisconsin Sequence Analysis Package GCG (Genetics Computer Group, University Research Park, Madison), Version 9.1, 1997. The remainder of the amino acids may be different. A homology of 90% for example means that 90% of the amino acids of the protein are identical compared with the amino acid sequence given in SEQ ID NO: 1 whereas 10% of the amino acids may be different. The proteins of the present invention have, however, the biological activity of β , β -carotene 15,15'-dioxygenase which is explained above in more detail. In the present invention, this protein may be derived from other sources, for example, from other mammals, such as from humans.

As used herein, the terms "protein" and "polypeptide" are used interchangeably throughout. The terms "nucleic acid" and "polynucleotide" are likewise used interchangeably.

The term "nucleic acid" is intended to include, without limitation, DNA, RNA, cDNA, and mRNA. As used herein, the DNA may be genomic, synthetic, or semi-synthetic. Moreover, the nucleic acids of the present invention include single-stranded and double stranded molecules.

As used herein "derived from" means that the protein, polypeptide, and/or polynucleotide exists naturally in an organism, such as for example, a chicken. However, the polypeptides and polynucleotides of the present invention may be produced/obtained from any source. Thus, the present invention includes recombinant, synthetic and semi-synthetic proteins, polypeptides, and polynucleotides.

The compositions of the present invention are said to be "isolated," such as for example "isolated polypeptide," "isolated polynucleotide," etc. As used herein, the term

"isolated" is intended to mean that the polypeptide or polynucleotide is purified or, at least partially purified as described, for example, in Fig. 1.

Another aspect of the present invention concerns nucleic acid sequences coding for a protein having the biological activity of β , β -carotene 15,15'-dioxygenase. A nucleic acid sequence coding for the enzyme derived from chicken is shown in SEQ ID NO: 2 (see Figure 3). The nucleic acid sequences of the present invention code for a protein of the present invention or a part thereof. Shorter nucleotide sequences suitable for PCR have a length of at least 20 bases, preferably at least 25 bases and most preferred at least 30 bases.

The nucleic acid sequences of the present invention can be used as primers for the specific amplification of a gene or part thereof coding for β , β -carotene 15,15'-dioxygenase. Primers can also be used for the specific amplification of 5' nontranslating or 3' nontranslating sequences of the cDNA described above. The nucleic acid sequences of β , β -carotene 15,15'-dioxygenase cDNA can be used as a probe for the detection of the coding as well as for the noncoding regions or parts thereof. The nucleic acid sequences of the present invention can be used as antisense RNA probes for *in situ* hybridization.

It is especially preferred to use primers and probes having a part of the sequence given in SEQ ID NO: 2 as primers and/or probes in test kits which can be used for the amplification and/or detection of genes/mRNAs coding for β , β -carotene 15,15'-dioxygenase by the polymerase chain reaction (PCR). The selection of suitable parts of the nucleic acid sequence can be performed by the person skilled in the art without difficulties. A nucleic acid sequence used as a primer or probe is usually selected from a region which is highly conserved within the protein. Conserved means that the nucleic acid sequences of such regions of proteins obtained from different species are very similar.

On the other hand the preferred nucleic acid sequence should not be present in other nucleic acid sequences which do not code for β , β -carotene 15,15'-dioxygenase, because this might lead to false positive results. By aligning several sequences derived from

different species such regions can easily be determined. Although the nucleic acid can be a ribonucleic acid it is more preferred to have deoxyribonucleic acid sequences.

One preferred use in diagnostics is the detection of the presence of β,β -carotene 15,15'-dioxygenase in patients. There is variability in β -carotene cleavage potential among the human population. Humans with low dioxygenase levels (with e.g. mutations or polymorphisms in the gene for β,β -carotene 15,15'-dioxygenase) could be identified and selected for vitamin A supplementation.

A diagnostic kit based on PCR can be designed to detect frequent mutations in the dioxygenase gene. Another diagnostic option is quantification of mRNA by RT-PCR. With this diagnostic tool differences in expression of β,β -carotene 15,15'-dioxygenase in various tissues and in different species can be found.

Since the protein has been expressed and a method for purifying the protein is described in detail in the examples the person skilled in the art can use the protein or peptides derived from the amino acid sequences in order to generate antibodies which specifically react with the protein. It is either possible to produce polyclonal antibodies by immunizing laboratory animals, like rabbits, sheep or goats preferably with an adjuvant or monoclonal antibodies by the well-known technique described by Köhler and Milstein (European Journal of Immunology, 1976, 6 (7), p. 511-519). The antibodies should specifically react with β,β -carotene 15,15'-dioxygenase in order to avoid an unspecific crossreaction. This means that the antibodies of the present invention should preferably react with an epitope which is present only on a protein of the present invention.

Such antibodies can be preferably used in immunoassays for the detection and/or quantification of β,β -carotene 15,15'-dioxygenase in a test fluid. The test fluid may be a liquid, like serum, obtained from a patient. There are several types of immunoassays which are well-known to the person skilled in the art. Very frequently one antibody, preferably a monoclonal antibody is fixed to a solid phase. This antibody is then brought into contact

with the fluid containing the β,β -carotene 15,15'-dioxygenase and after washing it is further reacted with a second monoclonal antibody which binds to another epitope of the enzyme. The second antibody is usually labeled and shows the presence of the sandwich consisting of the antigen and two different antibodies.

5

The antibodies can also be used in laboratory methods like Western blots or immuno-precipitations. Preferably such antibodies can be used in immunohistochemistry to detect epitopes of β,β -carotene 15,15'-dioxygenase in embedded or fixed tissues or cells of any species of interest.

10

In a further embodiment of the present invention the β,β -carotene 15,15'-dioxygenase is used for the production of vitamin A whereby the enzyme cleaves enzymatically β -carotene into two molecules of retinal which will subsequently be reduced by retinol dehydrogenase to vitamin A. The β,β -carotene 15,15'-dioxygenase can be used to enzymatically convert β -carotene which may be obtained from plant sources. A preferred source of β -carotene is the alga *Dunaliella bardawil* which has a high endogenous level of β -carotene. Suitable algae can be grown conveniently and β -carotene can be purified therefrom at rather low cost. The carotene can be conveniently cleaved enzymatically by using a protein of the present invention. The carotene dioxygenase can preferably be immobilized in order to provide a continuous process.

15

20

Another aspect of the present invention concerns the introduction of the gene coding for a protein having β,β -carotene 15,15'-dioxygenase activity into a suitable host cell. The first step in such a method is usually to insert the cDNA into a suitable vector.

25

The vector must fit with the host cell into which the gene should be introduced. There are specific vectors available for bacteria, yeasts, plant cells, insect cells or mammalian cells. Preferably the gene is combined with genetic structures which provide the required genetic regulation like promoters, enhancers, ribosomal binding sites etc.

Systems for the expression of genes encoding carotenoid biosynthetic enzymes in procaryotes, especially in *E. coli* or *Bacillus subtilis* or *Flavobacter* and eucaryotes, e.g. fungi are known in the art and described e.g. in EP Publication Nos. 747 483 or EP 872 554.

The vector having the gene and the other required genetic structures is then introduced into suitable host cells by well-known methods like transformation, transfection, electroporation or microprojectile bombardment. Depending on the host cell it may be preferred to stably integrate the gene coding for a protein of the present invention into the genome of the host cell. The cells obtained by such methods can then be further propagated and if the cell is a plant cell it is possible to generate therefrom transgenic plants.

In one embodiment of the present invention the host cells are plant cells and tomato cells are especially preferred. The technology to produce transgenic tomatoes is well-established and the tomato contains sufficient β -carotene in order to come up with a reasonable vitamin A level after introduction of carotene dioxygenase into the tomato plant. In green pepper, melon or especially carrot the endogenous level of β -carotene is even higher and therefore also these plants are especially preferred.

Another preferred embodiment of the present invention concerns algae. Halotolerant algae may contain high levels of β -carotene. A transfection of such algae with an expression vector comprising the β , β -carotene 15,15'-dioxygenase cDNA leads to a high intracellular vitamin A level which can easily be recovered from such algae by simple purification steps.

In another aspect of the present invention a gene coding for a protein of the present invention can be introduced into mammalian cells and especially into human cells. It is for example possible to insert the gene coding for a β , β -carotene 15,15'-dioxygenase into suitable cells, for example peripheral blood stem cells. Such cells which contain the gene

for β,β -carotene 15,15'-dioxygenase may be administered to people having mutations or deletions in the β,β -carotene 15,15'-dioxygenase gene. Such mutations and deletions, respectively, may have the effect that such patients are not able to cleave β -carotene enzymatically. Therefore, such patients always have a low vitamin A level and thus suffer from various developmental and ophthalmological problems. The administration of suitably transfected cells expressing the β,β -carotene 15,15'-dioxygenase to such patients by way of somatic gene therapy is a way to improve their situation.

The following examples are provided to further illustrate methods of preparation of the enzyme of the present invention, as well as certain physical properties and uses thereof. These examples are illustrative only and are not intended to limit the scope of the invention in any way.

EXAMPLES

EXAMPLE 1

Assay of β,β -carotene 15,15'-dioxygenase activity

For the tests the following solutions were prepared:

- a) Solution 1 (mixed micelle solution): Glycocholic acid (1.16 g) was dissolved in 5 ml H_2O under stirring and by drop-wise addition of 5 N NaOH. After the pH was adjusted to 6.8-7.2 with acetic acid and the volume increased to 10 ml with H_2O , 80 mg of asolectin (Fluka) were added and dissolved under stirring.
- b) Solution 2 (substrate solution): 500 μ l of an α -tocopherol solution (10 mg/ml in hexane) and 235 μ g of a β -carotene solution (80 μ g/ml of pure all-E- β -carotene in benzene) were mixed in a glass vial, protected from light and the solvents evaporated under a gentle nitrogen stream. 1 ml of solution 1 was added under vortexing and eventually a few short ultrasonic bursts until a clear solution occurred.

c) Solution 3 (homogenization buffer): 100 mM KH_2PO_4 adjusted with 5 N KOH to pH 7.8 and containing 4 mM MgCl_2 , 6 H_2O and 30 mM nicotinamide.

d) Solution 4 (GSH solution): 60 mg/ml reduced glutathione dissolved in solution 3.

e) Solution 5 (standard solution): 10 $\mu\text{g/ml}$ vitamin A acetate in hexane/chloroform 9:1.

Activity Assay

2 ml of the enzyme preparation (approximately 4 mg protein, assayed by BCA protein assay, Pierce Chemicals) were placed in a light-protected glass vial in a shaking water bath (30 minutes, 37 °C). 0.2 ml of solution 4 was added and the reaction was started after 2 minutes of temperature equilibration by addition of 50 μl of solution 2. After 3 hours, the reaction was stopped by placing the vials on ice and subsequent addition of 1 ml acetonitrile followed by 5 ml chloroform. The vials were vortexed 3 times for 7 seconds and phase separation was obtained by centrifugation for 5 minutes at 5000 g. Extraction was repeated twice with 0.6 ml chloroform. The combined chloroform phases were evaporated and resolubilized in 200 μl solution 5 under short sonication. Insoluble material was removed by filtration through 0.45 μm filters. An aliquot of 20 μl was separated by HPLC on a reversed phase C₁₈ column (Lichrospher 100, 5 μm , 12.5 cm x 4.6 mm, Bischoff Chromatography, Leonberg, Germany; 1 ml/min, column temperature 25°C) with a discontinuous, optimized gradient of acetonitrile/tetrahydrofuran/(1% ammonium acetate in H_2O) from 50:20:30 (eluent A) to 50:44:6 (eluent B). These conditions allow complete separation of β , β -carotene and retinal as well as apo- β -carotenals and retinoic acids. Calibration curves were made for both β , β -carotene and retinal in the concentration ranges 2-40 ng/ μl and 1-10 ng/ μl , respectively, and were correlated to the value of vitamin A acetate which served as an internal standard. Enzymatic activity was expressed as the amount of retinal liberated in the activity assay during 3 hours of incubation at 37 °C (100% = 17.6 nmol).

EXAMPLE 2

Purification of β,β -carotene 15,15'-dioxygenase

Purification was done as rapidly as possible, and all buffers and equipment were cooled to 4 °C.

Solution 6 (protease inhibitor-containing homogenization buffer): 125 mM benzamidine-HCl, 250 mM 6-aminocaproic acid and 125 μ M soybean trypsin inhibitor were dissolved in H₂O by sonication. A 4 ml-*aliquot* of this solution was mixed with 100 ml of solution 3.

Solution 7: 10 mM KH₂PO₄, 1 mM reduced glutathione, pH 7.8.

Solution 8 (eluent A, phenyl-Sepharose chromatography): 10 mM KH₂PO₄, 1 mM reduced glutathione, 0.5 M (NH₄)₂SO₄, pH 7.8.

Solution 9 (eluent B, phenyl-Sepharose chromatography): 10 mM KH₂PO₄, 1 mM reduced glutathione, 10% glycerol, pH 7.8.

Solution 10 (eluent B, Poros HQ chromatography): 10 mM KH₂PO₄, 1 mM reduced glutathione, 0.5 M NaCl, 10% glycerol, pH 7.8.

Solution 11 (elution buffer for gel permeation chromatography): 50 mM KH₂PO₄, 1 mM reduced glutathione, 150 mM NaCl, 10% glycerol, pH 7.8.

Laying hens at an age of 20-24 weeks (strain Lohmann LSL, Hatchery Wuethrich, CH-3123 Belp, Switzerland) were kept on a pigment-free chicken diet (Kliba 3179, Kliba, CH-4303 Kaiseraugst, Switzerland). The animals were killed by decapitation and the first 20 cm of the duodenal loop was removed, separated from pancreas and rinsed with 40 mL

each of 0.9% NaCl solution. The intestines (duodenal loops) were immediately frozen in dry ice and stored at -80°C until use.

Ten intestines (duodenal loops) were thawed on ice in approximately 2 hours and opened length-wise in an ice cooled Petri dish. The mucosa was scraped off with a slide, weighed and homogenized in a Teflon-glass Potter-Elvehjem homogenizer in 4 volumes of solution 6 with six strokes. Upon centrifugation at 62000 g for 1 hour, the clear supernatant was divided into 32 aliquots of 15 ml each. From these preparations an ammonium sulphate fractionation was made. The precipitate obtained from the 20-45% step was centrifugated at 5000 g for 10 minutes and the pellet was stored at -80°C for further use.

Ten aliquots of the $(\text{NH}_4)_2\text{SO}_4$ pellet were dissolved in 150 ml of solution 7, sterile-filtered and loaded on a HiLoad 26/10 phenyl-Sepharose High Performance column (column volume 53 ml; Pharmacia, Uppsala, Sweden) and equilibrated with solution 8. Proteins were eluted at a flow rate of 8 ml/minute with a steep gradient over 1 column volume (CV) from solution 8 to solution 9. β , β -Carotene 15,15'-dioxygenase eluted at a conductivity of < 15 mS/cm, but only fractions with a conductivity of < 1 mS/cm were pooled and directly loaded onto a 30 ml Blue Sepharose 6 Fast Flow column (Pharmacia) equilibrated with solution 9. β , β -Carotene 15,15'-dioxygenase activity eluted (at a flow rate of 8 ml/min) in the break-through fractions which were (again) directly loaded onto a 20 ml Poros HQ/M anion exchange chromatography column (PerSeptive Biosystems, Framingham, MA, USA) equilibrated with solution 9. β , β -Carotene 15,15'-dioxygenase was eluted at a flow rate of 15 ml/minute with a linear gradient over 18 CV from solution 9 to solution 10. Activity was detected in the gradient in a conductivity range of 10-20 mS/cm. The pooled fractions (70 ml) were concentrated to ~1.3 ml with Ultrafree-15 filter units (MW cut-off 50,000; Millipore, Bedford, MA, USA). An aliquot of the concentrate (500 μ l) was loaded onto a Superdex 200 HR 10/30 gel filtration column (CV 24 ml; Pharmacia) and eluted at a flow rate of 0.5 ml/minute with solution 11. Aliquots of each fraction were used for activity assays (see example 1) and, upon concentration, for SDS-PAGE (with MOPS running buffer) on 10% NuPAGE gels (Novex, San Diego, CA, USA).

The results of this experiment are shown in Fig. 1 and Table 1.

TABLE 1

Purification step	Total protein (mg)	Total activity (nmol/h)	Yield (%)	Specific activity (pmol/(h·mg))	Purification factor
(NH ₄) ₂ SO ₄ pellet	779	8.61	100	11.0	—
phenyl-Sepharose Blue	80.8	8.27	96.1	102	9.27
Sepharose Poros HQ	16.0	8.86	103	554	50.1
	1.56	3.90	45.3	2500	226

Table 1: Summary table for the purification of β,β -carotene 15,15'-dioxygenase starting with 10 aliquots of the (NH₄)₂SO₄ pellet (means of 3-4 measurements).

EXAMPLE 3

Amino acid sequence information for β,β -carotene 15,15'-dioxygenase

For amino acid sequence analysis, fractions of the gel filtration run (as shown in Fig. 1) were separated on a 8-16% Tris/glycine gel (Novex), and the proteins transferred to an Immobilon P[®] membrane (Millipore) and stained with amido black.

Since protein A proved to be N-terminally blocked, multiple aliquots of fraction 18 from the gel filtration run (see Fig. 1) were separated on a 10% Tris/glycine gel (Novex), and the gel was stained with Colloidal Coomassie Blue (Novex). The band corresponding to protein A was excised from the gel, and the protein digested in-gel with trypsin. The tryptic digest was separated by micro-bore reversed-phase HPLC on a 150 x 1.0 mm Vydac C₁₈ column (Vydac, Hesperia, CA, USA). Peptides were eluted with an acetonitrile gradient in 0.1% trifluoroacetic acid, and peptide containing fractions were collected for further analysis. Two fractions were identified by MALDI-TOF-MS (Voyager Elite,

PerSeptive Biosystems) to contain one single peptide each. N-terminal Edman degradation revealed the following sequences:

- (1) Ala-Glu-Val-Gln-Gly-Gln-Leu-Pro (Seq. ID No. 3)
- (2) Asn-Lys-Glu-Glu-His-Pro-Glu-Pro-Ile-Lys-Ala-Glu-Val-Gln-Gly-Gln-Leu-Pro (Seq. ID No. 6)

Note that the last 8 amino acids of peptide (2) correspond to peptide (1).

EXAMPLE 4

Cloning the full length cDNA for the β,β -carotene 15,15'-dioxygenase

A) RNA isolation:

A 4 week old Vedette chicken was killed, the duodenum was removed, washed with sterile PBS and cut open with scissors. The mucosal layer was scraped off with a glass slide, weighed and homogenized immediately with a Polytron in 1 ml of Trizole reagent (Life Technologies) per 100 mg of tissue. Then the standard protocol from Life Technologies was followed. Poly A mRNA was isolated by the polyAtract mRNA Isolation kit from Promega Corporation, Madison.

B) PCR and RT-PCR:

In the peptide sequence NKEEHPEPIKAEVQQLP (peptide 2 of Example 3) (Seq. ID No. 7) two degenerate primers were designed: In order to have a lower degeneracy the base Inosin was used in one and in two wobble positions, respectively.

- 5' primer: 5'AAC AAR GAR GAS CAY CCI GA 3' (Seq. ID No. 8)
(20 mer with a degeneracy of 16x)

3' primer: 5'SAG CTG ICC CTG IAC YTC SGC 3' (Seq. ID No. 9)
(21 mer with a degeneracy of 8x)

R= A or G, S= C or G, Y= C or T

The oligos were synthesized on a Pharmacia Gene Assembler Plus using standard phosphoramidite chemistry. Deprotection was done with 1 ml conc. ammonium hydroxide solution (Applied Biosystems) and final desalting was performed with a NAP 10 column (Amersham Pharmacia Biotech).

For PCR 100 ng of chicken duodenal cDNA were taken as template and the following steps performed: 94°C 30''; 52°C 30''; 72°C 1' for 40 cycles. The resulting band of 51 bp was cut out from a 10% polyacrylamide gel, electroeluted on DEAE paper at 300 V for 1.5 hours, eluted from the DEAE paper once with 40 µl and twice with 30 µl 1.5 M NaCl, 5 mM Tris, 0.5 mM EDTA, precipitated with 2.5 volumes of ethanol 100% and 1 µg glycogen, washed with 0.5 ml of 80% ethanol, dried and dissolved in 20 µl TE (10 mM Tris, 1 mM EDTA).

The resulting fragment of 51 bp was cloned into pGEM-T Easy, a commercially available T/A cloning vector (Promega Corporation, Madison). The corresponding cDNA sequence was determined by automated fluorescent sequencing on a Vistra DNA Sequencer 725 (Amersham Pharmacia Biotech).

From the above DNA sequence a homologous forward primer was derived:

5' TCTGAAATTCCGGAGCCCATAAAGC 3' (primer diox12) (Seq. ID No. 10)

At the 5' end an EcoRI site (underlined sequence) was introduced; the following 17 nucleotides are homologous to the previously obtained dioxigenase sequence.

In a RT-PCR reaction a polyT/Not primer (commercially available from Invitrogen, San Diego) was used as reverse primer together with primer dioxy12.

One tube RT-PCR kit from Boehringer Mannheim was taken and the corresponding protocol followed:

mix 1:

18.3 μ l H₂O

2.5 μ l DTT (100 mM)

1.0 μ l dNTPs (10 mM)

1.0 μ l oligo dT/Not (0.2 μ g/ μ l) (3' primer)

1.0 μ l dioxy12 (5' primer) (20 μ M)

0.2 μ l RNase inhibitor (40 U/ μ l)

1.0 μ l chicken duodenal total RNA (2.2 μ g/ μ l)

25.0 μ l

mix 2:

14.0 μ l H₂O

10.0 μ l RT-PCR buffer 5x

1.0 μ l enzyme mix (AMV RT, Taq and Pwo DNA Polymerase)

25.0 μ l

The 2 mixes were combined and the PCR protocol started on a MJ Research PTC200 DNA Engine.

50°C 30'

94°C 2'

94°C 30''

57°C 30'' 10 cycles

68°C 45''

94°C 30''

62°C 30'' 25 cycles

68°C 45'' + 3'' /cycle

68°C 7'

4°C over night

With this RT-PCR protocol a band of 597 bp was amplified from chicken total duodenal RNA. The PCR band was isolated from a 1% agarose gel, cloned into pGEM-T Easy cloning vector and subsequently sequenced. The original peptide is present in the sequence as well as an open reading frame over the whole sequence of 597 bp.

C) Chicken cDNA-library:

From chicken duodenal polyA⁺ RNA cDNA was made with the Copy Kit (Invitrogen, San Diego) using a modified Gubler-Hoffman procedure. The cDNA was size-selected (0.9-5.5 kb) and cloned into the eukaryotic expression vector pcDNA1.1/Amp (Invitrogen).

Electroporation into *E. coli* Top10 was done with a Bio-Rad Gene Pulser II system following the standard protocol. This resulted in a cDNA library of 480,000 individual clones. The library was split into 250 pools with 1500-2500 individual clones each. Each pool was amplified in 100 ml LB medium: Bacterial growth was stopped at OD 0.8-1.0 by adding chloramphenicol to a final concentration of 170 µg/ml. Incubation was continued over night in order to increase the DNA amount.

D) Activity screening of the chicken cDNA library:

90 of the above pools were tested for activity in a transactivation assay based on the detection of retinoic acid which is produced in eukaryotic cells after β-carotene cleavage. The principle of the activity test is shown in Fig. 2.

5 µg of DNA from each pool were transfected with 20 µg of lipofectin (Life Technologies) into a reporter cell line bearing a luciferase reporter plasmid with a RARE

(retinoic acid response element) in front of the tk promoter (Herpes simplex thymidine kinase promoter). Transfections were done for 7 hours under serum free conditions. After 7 hours the transfection mix was removed and RPMI medium with 10% charcoal treated FCS (fetal calf serum) was added. After 20 hours of incubation β -carotene (β -carotene 10% CWS, F. Hoffmann-La Roche Ltd.) or a placebo formulation were added to the culture medium to a final β -Carotene concentration of 5 μ M. Incubation was continued for 18 hours. Then cells were washed with PBS, and luciferase expression was measured after substrate addition with a nitrogen cooled slow scan CCD camera (AstroCam Ltd.) Exposure time usually was 8 min. Analysis was done with the Image Pro Plus 3.0 software package (Media Cybernatic, Maryland). 3 pools were strongly positive, 7 pools showed weaker, but detectable activity.

One of the positive pools was plated on a square agar plate. 2 filters (nylon membranes, Gene Screen, NEN Research Products, Boston) were processed and screened with the radioactively (α^{32} P) dATP, Amersham) labeled 597 bp PCR-fragment. From 9500 colonies screened, 14 were double positive. From 36 colonies picked, 5 showed the same pattern after restriction site analysis. 2 clones were sequenced from the 5' end and the original 51 bp sequence was found. Subsequently the whole cDNA was sequenced and confirmed twice.

All molecular biological procedures were done according to Sambrook, Fritsch and Maniatis, Laboratory Manual, Cold Spring Harbor Laboratory Press (1989), which is incorporated by reference as if recited in full herein, if not otherwise mentioned.

The obtained cDNA sequence is shown in Figure 3 and the amino acid sequence deduced therefrom in Figure 4.

Figure 4 shows the derived amino acid sequence having 526 residues.

EXAMPLE 5

Sequence comparison

By sequence comparison with the EMBL Genbank a high homology between the known protein RPE65 (Hamel et al., J.Biol.Chem. (1993) p. 15751-15757) and the β , β -carotene 15,15' dioxygenase was found. A homology of 55.5% on the amino acid level was found. The sequence alignment is shown in Figure 5.

EXAMPLE 6

Expression of the cDNA for β , β -carotene 15,15'-dioxygenase in *E. coli*

With PCR the coding sequence of the β , β -carotene 15,15'-dioxygenase cDNA was amplified and the resulting fragment of 1578 bp was cloned into the EcoRI/BamHI site of the prokaryotic expression vector pQE-12 (Qiagen). The vector contains an in frame hexa-His affinity tag at the C-terminus of the dioxygenase. In addition, this plasmid contains a regulated promoter with two lacI repressor binding sites.

The *E. coli* strain M15pREP4 was transformed with the expression plasmid. For expression 1 l LB medium, containing 100 μ g/ml ampicillin and 25 μ g/ml kanamycin, was inoculated with 30 ml of an overnight culture. Growth was allowed until OD₆₀₀ of 0.6-0.8 was reached. At this point the culture was induced with 1 mM IPTG (isopropyl- β -thiogalactoside) and growth continued for another 1.5-2 hours. Bacteria were harvested by centrifugation and the pellet was frozen at -80°C.

The pellet was thawed by stirring in 20 ml extraction buffer (300 mM NaCl, 50 mM NaH₂PO₄, 20 mM Tris-HCl, 1 mg/ml Tween 40; pH 7.8) including 2.5 mg/ml dodecyl- β -D-maltoside. 1 ml protease inhibitor cocktail (5.9 mM benzamidine-HCl, 10 mM 6-amino-caproic acid, 5 μ M soybean trypsin inhibitor) was added at the same time.

The bacterial cells were lysed by a 4 minute treatment with a Polytron (Kinematica AG, Switzerland) using a PT7 unit following a 4 minute sonication with a Branson Sonifier 250.

The lysate was spun at 12000 x g and the supernatant purified over a Co²⁺-chelate column (Talon Superflow Resin, Clontech, Heidelberg, Germany). The protein was eluted with 15-20 ml of extraction buffer containing 150 mM imidazole.

The fractions were loaded on a 10% polyacrylamide gel and the protein containing fractions dialyzed against 150 mM tricine, 5 mM FeSO₄, 3 mg/ml reduced glutathione, 0.21 mg/ml sodium cholate. The gel is shown in Fig. 6. The samples were then assayed in the dioxygenase activity assay.

EXAMPLE 7

Expression of recombinant β - β -carotene 15,15'-dioxygenase in the human duodenal cell line HuTu80

With PCR the coding sequence of the β - β -carotene 15,15'-dioxygenase cDNA was amplified and the resulting fragment of 1578 bp was cloned into the BamHI/XhoI site of the plasmid pSFV₂gen. This vector is part of the Semliki Forest Virus expression system, which works highly efficiently in most mammalian cells.

The plasmid was used for *in vitro* synthesis of recombinant RNA, which was subsequently electroporated together with a helper virus into BHK cells (baby hamster kidney cells) for production of a high titer virus stock. With an aliquot of this stock the human duodenal cell line HuTu80 was infected. 16-18 hours after infection the cells were harvested and the pellet frozen at -80°C. Either the whole cell pellet, the cytoplasmic fraction or the membrane fraction was used in an activity assay. β - β -carotene 15,15'-dioxygenase activity was found in the whole cell extract and in cytosolic fractions, while in the membrane fraction no activity was detected.

EXAMPLE 8

5 **β - β -carotene 15,15'-dioxygenase activity of the
recombinant protein expressed in *E. coli* and in human cells**

10 After expression in *E. coli* and purification over a metal chelate column, the protein shows cleavage activity with β -carotene as substrate. Retinal was the only product detected by HPLC after incubation with β -carotene. No apocarotenals or other metabolites were found. This was proved by HPLC analysis as shown in Figs. 7 and 8.

15 The invention being thus described, it will be obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the invention and all such modifications are intended to be included within the scope of the following claims.

What Is Claimed Is:

- 5 1. An isolated polypeptide having β,β -carotene 15,15'-dioxygenase activity comprising SEQ ID NO: 1 or a polypeptide having β,β -carotene 15,15'-dioxygenase activity and being at least 60% homologous to SEQ ID NO: 1 as determined by the Wisconsin Sequence Analysis Package GCG, Version 9.1 (1997).
- 10 2. An isolated polypeptide according to claim 1 wherein the polypeptide is at least 70% homologous to SEQ ID NO: 1.
- 15 3. An isolated polypeptide according to claim 1 wherein the polypeptide is at least 80% homologous to SEQ ID NO: 1.
- 20 4. An isolated polypeptide according to claim 1 wherein the polypeptide is at least 90% homologous to SEQ ID NO: 1.
- 25 5. An isolated polypeptide according to claim 1 which is derived from chicken.
6. An isolated nucleic acid sequence encoding the polypeptide of claim 1.
7. An isolated nucleic acid sequence according to claim 6 which comprises SEQ ID NO: 2 or a fragment thereof.
- 25 8. An isolated nucleic acid sequence according to claim 7 wherein the fragment has at least 20 bases.
- 30 9. An isolated nucleic acid sequence according to claim 7 wherein the fragment has at least 30 bases.

10. An isolated nucleic acid sequence according to claim 6 wherein the nucleic acid is a deoxyribonucleic acid.

11. An isolated nucleic acid sequence according to claim 6 wherein the nucleic acid is an antisense ribonucleic acid.

12. A primer for amplifying a gene coding for a polypeptide having β,β -carotene 15,15'-dioxygenase activity which primer comprises a fragment of the nucleic acid sequence according to claim 6.

13. A probe for detecting a gene coding for a polypeptide having β,β -carotene 15,15'-dioxygenase activity which probe comprises a fragment of the nucleic acid sequence according to claim 6.

14. A test kit for amplifying and/or detecting a gene or a fragment thereof coding for β,β -carotene 15,15'-dioxygenase wherein the test kit comprises at least one primer according to claim 12.

15. A test kit for amplifying and/or detecting a gene or a fragment thereof coding for β,β -carotene 15,15'-dioxygenase wherein the test kit comprises at least one probe according to claim 13.

16. An antibody which specifically reacts with a polypeptide according to claim 1.

17. An immunoassay for the detection and/or quantification of β,β -carotene 15,15'-dioxygenase which comprises at least one antibody according to claim 16.

18. A process for the production of vitamin A comprising enzymatically cleaving β -carotene with a polypeptide according to claim 1.

19. A method for introducing a β,β -carotene 15,15'-dioxygenase cDNA into a host cell comprising introducing a cDNA coding for the polypeptide of claim 1 into a vector suitable for the host cell and introducing the vector into the host cell.
20. A method according to claim 19 wherein the host cell is a plant cell.
21. A method according to claim 19 wherein the host cell is a prokaryotic cell.
22. A method according to claim 19 wherein the host cell is a yeast cell or a fungal cell.
23. A method according to claim 19 wherein the host cell is an alga cell.
24. A method according to claim 19 wherein the host cell is a mammalian cell.
25. A method according to claim 24 wherein the mammalian cell is a human cell.
26. A host cell obtained by the method of claim 19.
27. A host cell according to claim 26 which comprises a β,β -carotene 15,15'-dioxygenase cDNA obtained from another species.
27. An isolated polynucleotide which encodes β,β -carotene 15,15'-dioxygenase comprising SEQ ID NO: 2.
28. An isolated polynucleotide according to claim 27 which consists essentially of SEQ ID NO: 2.
29. An isolated polynucleotide according to claim 27 which consists of SEQ ID NO: 2.
30. A vector comprising the polynucleotide of SEQ ID NO: 2.

31. A host cell transformed with the vector of claim 30.

32. An isolated polypeptide having β,β -carotene 15,15'-dioxygenase activity
5 comprising SEQ ID Nos: 1 or 4.

33. A primer set for amplifying a polynucleotide encoding β,β -carotene 15,15'-
dioxygenase comprising SEQ ID NO: 8 as a 5' primer and SEQ ID NO: 9 as a 3' primer.

10 34. A primer set for amplifying a polynucleotide encoding β,β -carotene 15,15'-
dioxygenase comprising a polyT/Not reverse primer and SEQ ID NO:10 as a forward
primer.

15 35. A kit for amplifying and/or detecting a polypeptide or fragment thereof encoding
 β,β -carotene 15,15'-dioxygenase comprising at least one primer selected from the group
consisting of SEQ ID Nos: 8, 9, and 10.


ABSTRACT OF THE DISCLOSURE

5

Nucleic acid sequences coding for a protein having β,β -carotene 15,15'-
dioxygenase activity and their uses in diagnostics, the synthesis of vitamin A and methods
for the introduction of the β,β -carotene 15,15'-dioxygenase cDNA into host cells are
disclosed.

10

Figure 1






Figure 2

Figure 3
No. 2

Seq. ID

1 CGGATCCACT AGTAACGGCC GCCAGTGTGG TGGAAATCCAT
CCTTCTATGT

51 AACAGGAAAG AGCTGTTCTT AGCCCAGAGA GGAGGGCACC
GTACGCCCTGC

101 AGGAGCAGCT GGGTAGAGGA CACAGGAGAG CGATGGAGAC
AATATTTAAC

151 AGAAACAAAG AAGAGCATCC AGAGCCCAT AAGCTGAGG
TGCAAGGTCA

201 GTTGCCCACT TGTTGCAAG GGGTACTTCT CCGAAATGGC
CCAGGGATGC

251 ACACAATAGG GGACACTAAA TACAACCACT GGTTCATGG
CTTGGCTCTG

301 CTGCACAGCT TCACGTTTAA AAATGGTGAA GTTTACTACA
GAAGTAAGTA

351 CCTCCGAAGT GACACATACA ACTGCAATAT AGAAGCAAAC
CGAATCGTGG

401 TGTCTGAGTT TGGAAACATG GCTTATCCGG ATCCATGCAA
AAACATATTT

451 GCCAAGGCAT TCTCATACTT ATCTCACACC ATTCTGAGT
TCACGGACAA

501 CTGCCTGATC AACATTATGA AAAGTGGGA TGATTATTAT
GCTACCACTG

551 AGACTAACTT CATCAGAAAA ATTGATCCAC AGACTCTGGA
GACACTAGAT

601 AAGGTAGACT ACAGCAAATA TGTAGCTGTA AACTTGGCAA
CTTCTCACCC

651 AACTATGAC AGTGCTGGAA ATATTCTCAA CATGGGTACT
TCAATTGTTG

701 ATAAAGGGAG AACAAAATAT GTTCTCTTTA AGATCCCTTC
CTCTGTACCA

751 GAAAAAGAAA AGAAGAAATC TTGTTTTTAA CACCTGGAAG
TAGTATGCTC

801 CATCCCTTCT CGCTCCCTGC TCCAACCAAG CTACTACCAC
AGCTTTGGAA

851 TCACAGAAAA TTATATTGTG TTCATAGAGC AGCCATTAA
ACTGGATATT

901 GTCAAACTGG CAACTGCCTA CATCCGAGGT GTGAAC TGGG
CTTCCTGCCT

951 TTCCTTTCAT AAGGAGGATA AGACGTGGTT TCACTTTGTA
GACAGAAAGA

1001 CGAAAAAAGA AGTATCCACC AAGTTT TACA CTGATGCTTT
GGTGCTTTAT

1051 CACCACATAA ATGCTTACGA AGAAGATGGC CACGTTGT TT
TTGATATCGT

1101 TGCC TACAGA GACAATAGCT TGTACGATAT GTTTTACTTA
AAAAAACTGG

1151 ACAAAGACTT TGAAGTGAAC AACAAGCTTA CCTCCATCCC
AACCTGCAAG

1201 CGCTTTGTTG TGCCCTCTGCA GTATGACAAG GATGCAGAAG
TAGGTTCTAA

1251 TTTAGTCAAA CTTC CAACTT CCGCAACTGC TGTAAAAGAA
AAAGATGGCA

1301 GCATCTATTG TCAACCTGAA ATATTATGTG AAGGGATAGA
ACTGCC TCGT

1351 GTCAACTATG ACTACAATGG CAAAAAATAC AAGTATGTCT
ATGCAACAGA

1401 AGTCCAGTGG AGCCCAGTTC CTACAAAGAT TGCAAACTG
AATGTCCAAA

1451 CAAAGGAAGT ACTGCACTGG GGAGAAGACC ACTGCTGGCC
CTCAGAGCCC

1501 ATCTTTGTTC CCAGCCCCGA TGCAAGAGAA GAGGATGAAG
GTGTTGTTTT

1551 GACCTGTGTT GTGGTGTCTG AGCCAAATAA AGCACCTTC
CTACTCATCT

1601 TGGATGCTAA AACATTCAAA GAATTGGGCC GAGCCACAGT
TAACGTAGAA

1651 ATGCATCTGG ACCTGCATGG GATGTTTATA CCACAGAATG
ATTTGGGGGC

1701 TGAGACGGAA TAAACGCTA TTGATCCGAC TACACAACT
GAGACAACTT

1751 TCTACTGAAC ATGAGTTAAT ATCCCTTTTA CCATTCAAGA
ACAACCATAT

1801 AACGACACAA AATGACTATG TATAATCTCT TAAATAATAG
ATATAATCCT

1851 TTTAAGGCAC AGCGATGAGT TTTACTACAG GTAACGATAT
GCACAACTGG

1901 CATATAACTA TTCCAAAAGA AGAAGAACGA TCAGTGT'TTT
AGAAGTGCTA

1951 ATGTTGTACA TAACGGCGGC AGAGGGAACA GGAGAGAAAG
GTAACGGGAA

2001 TATTTAATAG AATATAGATT TCTGAGCAAA TGAAGTGCAG
TATTTATGGT

2051 GTGATGCATG GCATGAGTCA CATAGGTCTG CAGCTCATGT
ATCTTTTAGA

2101 GATCGTTTCA AGATTGCAGC TTGTGATGCA AGTTTTC'TCC
AGCCAGAAAA

2151 CCTCATTTTA AACCATCTGC TACTGGTAAT TCATACCAAT
GCATTTTCTT

2201 GGTGCTCGAT TTACACTATA ACCAAAGTTA AGTATTACAT
TCAGGTGCTA

2251 CAAC'TTTCTA ATTTACAACC GAAACAAACA AGCAAACAGC
ACTTGC'TTTG

2301 CTAATAACCC CATGGTGTAT TTTTCCTTTT TATGATGACA
AAACCAAGTA

2351 CATATGGTTT TATGTAGCAT TCAATTATAC TTCAGTGCTA
TTCCATCCTA

2401 ATGTTATAAG CAATTTGTAT TTAAATCAGT TTTCTTTGAG
AATATCTGAC

2451 ATAACATTTT GTGTAATGAG ATGACTATGT TGTCTAAAGA
TGAACAGGAA

2501 TGTATCTTTT ATTAGTATTG TTAATTGTGT TACTAATACT
ATGCATATGA

2551 ATGAGAGCAA TGTATTTCTA GGAGAACTCA GATATACATT
CAACAATTTC

2601 TGTAGGTGAA AATGCATTTA CTGATGAAAG TTGAATCGTT
AATGAGGGAG

2651 AAAACTGGGT ATCCATCCAT CCAACTATGT TAGGTGTTCA
CCTGGTCTGT

2701 ATGTGACACC ACGCTGTTTG GGTATCTCTC ACTTTCACAT
ACCTGTTCTC

2751 ATGGTTTCTG CTA'CTCACTG TATTTTGCAG GAGAGAAACA
AAATGAAATC

2801 ACTGTCAC'TT ACTATCGCCC CATCACATAA GAACAATGGG
GCTTTGGTGA

2851 CTTGTTTCATG ATTACATAAG ATGTTTGCAG CAGAGCAGCA
ATAGAACCAA

2901 CACCATCCAC AGTTCTTGCT TGCTCTGTTA TGACTCCCTT
TGCTGTCTTT

2951 ATGGTTTGCA TGTATGAAGA ATACACTGCC TAATTC TAAT
GTTAAAAAGT

3001 CACTGGGGTC AGATCTAGAG CTTAAGTAAG CAGTCTGGGG
TTTTCAAATG

3051 TTTATATGTT CCATAAAATG GAAATAAACA CCTCCATAAT
AAAAAAAAAA

3101 AAAAAAAAAA A

Figure 4
No. 1

Seq. ID

1 METIFNRNKE EHPEPIKAEV QQQLPTWLQG VLLRNGPGMH
TIGDTKYNHW

51 FDGLALLHSF TFKNGEVYR SKYLRSDTYN CNIEANRIVV
SEFGTMAYPD

101 PCKNIFAKAF SYLSHTIPEF TDNCLINIMK TGDDYYATSE
TNFIRKIDPQ

151 TLETLDKVDY SKYVAVNLAT SHPHYDSAGN ILNMGTSIVD
KGRTKYVLFK

201 IPSSVPEKEK KKSCFKHLEV VCSIPSRSL L QPSYYHSFGI
TENYIVFIEQ

251 PFKLDIVKLA TAYIRGVNWA SCLSFHKEDK TWFHFVDRKT
KKEVSTKFYT

301 DALVLYHHIN AYEEDGHVVF DIVAYRDNLS YDMFYLK KLD
KDFEVNKNLT

351 SIPTCKRFVV PLQYDKDAEV GSNLVKLPTS ATAVKEKDG
IYCQPEILCE

401 GIELPRVNYD YNGKKYKYVY ATEVQWSPVP TKIAKLNQV
KEVLHWGEDH

451 CWPSEPIFVP SPDAREEDEG VVLTCVVVSE PNKAPFL LIL
DAKTFKELGR

501 ATVNVEMHLD LHGMFIPQND LGAETE

Figure 5

Seq ID No. 4 and Seq ID No. 5

10 EEHPEPIKA[·]EVQQLPTWLQ[·]GVLLR[·].NGPGMHTIGDTKY[·]NHWFDGLALL[·]
 57 || | : | | | : | | | | | : | : | | | | |
 20 EELSSPLTAHV[·]TGRIPLWLTGSL[·]LRCTGPGLE[·]VGSEPFYHLFDGQALL[·]
 69
 58 HSFTFKNGEVY[·]YRSKYLRSDTYNCNIEANRIVVSEFG[·].TMAYPDPCCKNI[·]
 105 | | | | | : : | | | : | | | | | : | | | | |
 70 HKFDFKEGHV[·]TYHRRFIRTDAYVRAMTEKRIVITEFGFTTCAFPDPCCKNI[·]
 119
 106 FAKAFSYLSHTI[·]PEFTDNCLINIMKTGDDYATSETNFI[·]RKIDPQ[·]TLETL[·]
 155 | : | | | | | | | | : : | : | | | | | | | : | | | :
 120 FSRFFSYFRGV[·].EVTDNALVNVPVGEDYYACTETNFI[·]TKINPETLETI[·]
 167
 156 ..DKVDYSKY[·]VAVNLATSHPHYDSAGNILNMGTSIVDKGR[·]TKYVLFKIP[·]S
 203 | | | | | | | | : | : | : | | | : | | |
 168 FTKQVDLCN[·]YVSVNGATAHPHIENDGTVYNIGNCFGKNFSIAYNIVKIPP[·]
 217
 204 SVPEKEKKK[·]SCFKHLEVVC[·]SIPSRLLQPSYYHSFGITENYIVFIEQPPK[·]
 253 : | | | | | | : | | | | | | | | | | | | | | |
 218 LQADKEDPISK[·]FTS.EIVVQFPCSDRFKPSYVHSFGLTPNYIVFVETPVK[·]
 266
 254 LDIVKLATAY[·].IRGVNWA[·]SL.SFHKEDK.TWFHFVDRKTKKEVSTK[·]FYT[·]
 300 : : | : : : | : | | | | | | | : | | | | : : |
 267 INLFKFLSSW[·]SLWGANYMDCFESFTNETMGVWLHIADKRRKYLNNKYRT[·]
 316
 301 DALVLYHHINAYEEDGHV[·]VFDIVAYRDN[·]SL...YDMFYLKKLKD[·]KDFE...
 344 | : | | | | | : | : | : : | | | | | | | | | | |
 317 SPFNLFHHINTYEDNGFLIVDLCCWKGFEFVYNYFTLYLANLRENWEEVK[·]
 366
 345 VNNKLTSIPTCKRFV[·]VPLQYDKDAEVGSNLVKLP.TSATAV[·]..KEKDGS[·]I
 391 | : | | | : | : | | | | | | | | | : : | | |
 367 KNARKAPQ[·]PEVRRYVLPLNIDK.ADTGKNLVTL[·]PNTTATAILCSD[·]FEFTTI[·]
 415
 392 YCQEILCEG[·]....IELPRVNYD.YNGKKYKYVYATEVQ[·]WSPVPTKIAKL[·]
 436 : : | : | | | : | | | | | | | | | | : : | | |
 416 WLEPEVLV[·]SGPRQAFEPQIN[·]YQKYCGKPYTYAYGLGLNHF.VPDRLCKL[·]
 464

[illegible]




Fig. 6 shows a 10% polyacrylamide gel with E.coli expressed β,β -carotene 13,15'-dioxygenase after affinity tag purification; lane 1 and lane 2: 2 fractions from the Co^{3+} -chelate column showing the main band at 60 kD; lane 3: low range molecular weight marker (Bio Rad).




Fig. 7 shows an HPLC profile of the reaction mixture at the end of an activity assay for the β , β -carotene 15,15'-dioxygenase following the procedure in example 1. The first peak in the chromatogram represents the internal standard, while the second peak corresponds to retinal as the only product formed during the central cleavage with β -carotene as substrate.




Fig. 8 confirms that the product peak in Fig. 7 is indeed retinal. A sample which was positive in the activity assay (green chromatogram) was spiked with retinal and analysed in second HPLC run (red chromatogram). The chromatograms of the two runs were then overlayed.

Declaration and Power of Attorney for Patent Application

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

β, β-CAROTENE 15, 15'-DIOXYGENASES, NUCLEIC ACID SEQUENCES CODING THEREFOR AND THEIR USE

the specification of which

(check one)

☒ is attached hereto

☐ was filed on _____ as

Application Serial No. _____

and was amended on _____
(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, § 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

Priority Claimed

99103382.0 Europe 22 / February / 1999
(Number) (Country) (Day/Month/Year Filed)

☒ ☐
Yes No

(Number) (Country) (Day/Month/Year Filed)

☐ ☐
Yes No

(Number) (Country) (Day/Month/Year Filed)

☐ ☐
Yes No

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (*list name and registration number*)

Mark E. Waddell	(Reg.No. 31803)	Stephen M. Haracz	(Reg.No. 33397)
Warren K. MacRae	(Reg.No. 37876)	Timothy E. Tracy	(Reg.No. 39401)
Kevin C. Hooper	(Reg.No. 40402)	Kathleen Gersh	(Reg.No. 41806)
Leo G. Lenna	(Reg.No. 42796)	Robert J. Lipka	(Reg.No. 42807)

Send Correspondence to:

Mark E. Waddell, Esq., Bryan Cave LLP, 245 Park Avenue, New York, NY 10167-0034

Direct Telephone Calls to: (name and telephone number)

Mark E. Waddell - (212) 692-1800

Full name of sole or first inventor

Heinrich Bachmann

Inventors signature

Date

Residence

CH-4451 Wintersingen, Switzerland

Citizenship

Swiss

Post Office Address

42 Hauptstrasse, CH-4451 Wintersingen, Switzerland

Full name of sole or second inventor

Roland Bruggier

Inventors signature

Date

Residence

D-79106 Freiburg, Germany

Citizenship

German

Post Office Address

21 Egonstrasse, D-79106 Freiburg, Germany

(Supply similar information and signature for third and subsequent joint inventors.)

Full name of sole or third inventor, if any

Arno Martin Friedlein

Inventors signature

Date

Residence

D-79189 Bad Krozingen, Germany

Citizenship

German

Post Office Address

10 Dornröschenweg, D-79189 Bad Krozingen, Germany

Full name of sole or fourth inventor, if any

Gabriele Margarethe Wirtz

Inventors signature

Date

Residence

D-42349 Wuppertal, Germany

Citizenship

German

Post Office Address

19 Roehnstrasse, D-42349 Wuppertal, Germany

Full name of sole or fifth inventor, if any

Wolf-Dietrich Woggon

Inventors signature

Date

Residence

CH-4102 Binningen, Switzerland

Citizenship

German

Post Office Address

89 Dorenbachstrasse, CH-4102 Binningen, Switzerland

Full name of sole or sixth inventor, if any

Adrian Wyss

Inventors signature

Date

Residence

CH-4313 Möhlin, Switzerland

Citizenship

Swiss

Post Office Address

9 Föhrenstrasse, CH-4313 Möhlin, Switzerland

Full name of sole or seventh inventor, if any

Markus Wyss

Inventors signature

Date

Residence

CH-4410 Liestal, Switzerland

Citizenship

Swiss

Post Office Address

9 Rotackerstrasse, CH-4410 Liestal, Switzerland

Title 37, Code of Federal Regulations, §1.56, duty to disclose information material to patentability (in part) provides, in part, that each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is cancelled or withdrawn from consideration, or the application becomes abandoned.

Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and

- (1) It establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim: or
- (2) It refutes, or is inconsistent with, a position the applicant takes in:
 - (i) Opposing an argument of unpatentability relied on by the Office, or
 - (ii) Asserting an argument of patentability.

SEQUENCE LISTING

<110> BACHMANN, Heinrich
BRUGGER, Roland
FRIEDLEIN, Arno M
WIRTZ, Gabriele M
WOGGON, Wolf-Dietrich
WYSS, Adrian
WYSS, Markus

<120> BETA,BETA-CAROTENE 15,15'-DIOXYGENASES, NUCLEIC ACID
SEQUENCES CODING THEREFOR AND THEIR USE

<130> B,B-CAROTENE 15,15'-DIOXYGENASES,...

<140>

<141>

<150> 103382.0

<151> 1999-02-22

<160> 10

<170> PatentIn Ver. 2.1

<210> 1

<211> 526

<212> PRT

<213> CHICKEN

<400> 1

Met	Glu	Thr	Ile	Phe	Asn	Arg	Asn	Lys	Glu	Glu	His	Pro	Glu	Pro	Ile
1					5				10					15	

Lys	Ala	Glu	Val	Gln	Gly	Gln	Leu	Pro	Thr	Trp	Leu	Gln	Gly	Val	Leu
	20						25						30		

Leu	Arg	Asn	Gly	Pro	Gly	Met	His	Thr	Ile	Gly	Asp	Thr	Lys	Tyr	Asn
	35						40						45		

His	Trp	Phe	Asp	Gly	Leu	Ala	Leu	Leu	His	Ser	Phe	Thr	Phe	Lys	Asn
	50						55						60		

Gly	Glu	Val	Tyr	Tyr	Arg	Ser	Lys	Tyr	Leu	Arg	Ser	Asp	Thr	Tyr	Asn
65					70					75					80

Cys	Asn	Ile	Glu	Ala	Asn	Arg	Ile	Val	Val	Ser	Glu	Phe	Gly	Thr	Met
					85					90					95

Ala Tyr Pro Asp Pro Cys Lys Asn Ile Phe Ala Lys Ala Phe Ser Tyr
100 105 110

Leu Ser His Thr Ile Pro Glu Phe Thr Asp Asn Cys Leu Ile Asn Ile
115 120 125

Met Lys Thr Gly Asp Asp Tyr Tyr Ala Thr Ser Glu Thr Asn Phe Ile
130 135 140

Arg Lys Ile Asp Pro Gln Thr Leu Glu Thr Leu Asp Lys Val Asp Tyr
145 150 155 160

Ser Lys Tyr Val Ala Val Asn Leu Ala Thr Ser His Pro His Tyr Asp
165 170 175

Ser Ala Gly Asn Ile Leu Asn Met Gly Thr Ser Ile Val Asp Lys Gly
180 185 190

Arg Thr Lys Tyr Val Leu Phe Lys Ile Pro Ser Ser Val Pro Glu Lys
195 200 205

Glu Lys Lys Lys Ser Cys Phe Lys His Leu Glu Val Val Cys Ser Ile
210 215 220

Pro Ser Arg Ser Leu Leu Gln Pro Ser Tyr Tyr His Ser Phe Gly Ile
225 230 235 240

Thr Glu Asn Tyr Ile Val Phe Ile Glu Gln Pro Phe Lys Leu Asp Ile
245 250 255

Val Lys Leu Ala Thr Ala Tyr Ile Arg Gly Val Asn Trp Ala Ser Cys
260 265 270

Leu Ser Phe His Lys Glu Asp Lys Thr Trp Phe His Phe Val Asp Arg
275 280 285

Lys Thr Lys Lys Glu Val Ser Thr Lys Phe Tyr Thr Asp Ala Leu Val
290 295 300

Leu Tyr His His Ile Asn Ala Tyr Glu Glu Asp Gly His Val Val Phe
305 310 315 320

Asp Ile Val Ala Tyr Arg Asp Asn Ser Leu Tyr Asp Met Phe Tyr Leu
325 330 335

Lys Lys Leu Asp Lys Asp Phe Glu Val Asn Asn Lys Leu Thr Ser Ile
340 345 350

Pro Thr Cys Lys Arg Phe Val Val Pro Leu Gln Tyr Asp Lys Asp Ala
 355 360 365

Glu Val Gly Ser Asn Leu Val Lys Leu Pro Thr Ser Ala Thr Ala Val
 370 375 380

Lys Glu Lys Asp Gly Ser Ile Tyr Cys Gln Pro Glu Ile Leu Cys Glu
 385 390 395 400

Gly Ile Glu Leu Pro Arg Val Asn Tyr Asp Tyr Asn Gly Lys Lys Tyr
 405 410 415

Lys Tyr Val Tyr Ala Thr Glu Val Gln Trp Ser Pro Val Pro Thr Lys
 420 425 430

Ile Ala Lys Leu Asn Val Gln Thr Lys Glu Val Leu His Trp Gly Glu
 435 440 445

Asp His Cys Trp Pro Ser Glu Pro Ile Phe Val Pro Ser Pro Asp Ala
 450 455 460

Arg Glu Glu Asp Glu Gly Val Val Leu Thr Cys Val Val Val Ser Glu
 465 470 475 480

Pro Asn Lys Ala Pro Phe Leu Leu Ile Leu Asp Ala Lys Thr Phe Lys
 485 490 495

Glu Leu Gly Arg Ala Thr Val Asn Val Glu Met His Leu Asp Leu His
 500 505 510

Gly Met Phe Ile Pro Gln Asn Asp Leu Gly Ala Glu Thr Glu
 515 520 525

<210> 2

<211> 3111

<212> DNA

<213> CHICKEN

<400> 2

cggatccact agtaacggcc gccagtggtg tggaatccat cttctatgt aacaggaaag 60
 agctgttctt agccccagaga ggagggcacc gtacgcctgc aggagcagct gggtagagga 120
 cacaggagag cgatggagac aatatttaac agaaacaaag aagagcatcc agagccata 180
 aaagctgagg tgcaaggtca gttgccact tgggtgcaag ggggtactct cogaatggc 240
 ccagggatgc acacaatagg ggacactaaa tacaacctt ggttgatgg cttggctctg 300
 ctgcacagct tcacgtttta aaatggtgaa gtttactaca gaagtaagta cctccgaagt 360
 gacacataca actgcaatat agaagcaaac cgaatcgtgg tgtctgagtt tggaacatg 420

gcttatccgg atccatgcaa aaacatatatt gccaggcat tctcatactt atctcacacc 480
attcctgagt tcaacggcaa ctgcctgato aacattatga aaactgggga tgattattat 540
gctaccagtg agactaactt catcagaaaa attgatccac agactctgga gacactagat 600
aaggtagact acagcaaaata tgtagctgta aacttggcga cttctaccoc acactaccac 660
agtgtctgaa atattctctaa catgggtact tcaattgttg ataaagggag aacaaaatat 720
gttctcttta agatcccttc ctctgtacca gaaaaagaaa agaagaaatc ttgtttttaa 780
cacctggaaag tgatgtctc catccctctc cgctccctgc tccaaccaaag ctactaccac 840
agctttggaa tcacagaaaa ttatattgtg ttcataagag agccatttaa actggatatt 900
gtcaaacactgg caactgccta catccgaggt gtgaactggg cttctcgctt tctctttcat 960
aaggaggata agacgtgggt tcactttgta gacagaaaga cgaaaaaaga agtatccacc 1020
aagttttaca ctgattgctt ggtgctttat caccacataa atgcttacga agaagatggc 1080
cacgtgtttt ttgatatcgt tgctacaga gacaatagct tgtacgatat gttttactta 1140
aaaaaacctg acaagactt tgaagtgaac aacaagctta cctccatccc aacctgcaag 1200
cgctttgttg tgccctcgca gtatgacaag gatgcagaag taggttctaa tttagtcaaa 1260
cttcacactt ccgcaactgc tgtaaaagaa aaagatggca gcatctattg tcaacctgaa 1320
tatattatgt aagggataga actgcctcgt gtcaactatg actacaatgg caaaaaatac 1380
aagtgtctct atgcaacaga agtccagttg agcccagttc ctacaaagat tgcaaaactg 1440
aatgtccaaa caaagggaagt actgcactgg ggagaagacc actgctggcc ctcagagacc 1500
atctttgttc ccagcccgca tgcaagagaa gaggatgaag gtgtgtttt gacctgtgtt 1560
gtgtgtgtct agccaaataa agcacccttc ctactcatct tggatgtcaa aacattcaaa 1620
gaattggggc gagccacagt taacgtagaa atgcatctgg acctgcatgg gatgtttata 1680
ccacagaatg atttgggggc tgagacggaa taaaaagcta ttgatccgac tacacaaact 1740
gagacaactt tctactgaac atgagttaat atccctttta ccattcaaga acaaccatat 1800
aacgacaaa aatgactatg tataatctct taaataatag atataatcct ttaaggcac 1860
agcgatgagt ttactacag gtaacgatat gcacaactgg catataacta ttcacaaaga 1920
agaagaaaga tcagtgtttt agaagtgtca atgtgttaca taacggcgcc agaggggaaca 1980
ggagagaaag gtaacgggaa tattaatag aatatagatt tctgagctaa ttgaatcgag 2040
tatttttgtt gtgatgcatg gcatgagtca cataggtctg cagctcatgt atctttttaga 2100
gatcgtttca agattgcagc ttgtgatgca agttttctcc agccagaaaa cctcatttta 2160
aaccatctgc tactggtaat tcataccaat gcattttctt ggtgtctgat ttactata 2220
accaaagtta agtattacat tcagggtgcta caactttcta atttacaacc gaaaacaaa 2280
agcaaacagc acttgctttg ctaataaccc catggtgtat ttttctcttt tatgatgaca 2340
aaaccaagta catatggttt tatgtagcat tcaattatac ttcagtgtca ttcactcata 2400
atgtttataa caatttgtat ttaaatcagt ttcccttgag aatatctgac ataacatttt 2460
gtgtaatgag atgactatgt tgtctaaaga tgaacaggaa tgtatctttt attagtattg 2520
ttaatttgtt tactaatact atgcatatga atgagagcaa tgtattttca ggagaaactca 2580
gatataact caacaatttc tgtagggtgaa aatgcattta ctgatgaaag ttgaatcgtt 2640
aatgagggag aaaactgggt atccatccat ccaactatgt taggtgttca cctggctcgt 2700
atgtgacacc acgctgtttg ggtagctctc actttcacat acctgtcttc atgggtttctg 2760
ctactcactg tatttttcag gagagaaaca aaatgaaatc actgtcactt actatcgccc 2820
catcacataa gaacaaaggg gctttgttga ctgtttcact atcacataag attgtttgag 2880
cagagcagca atagaaccaa caccatccac agttcttctg tgctctgtta tgaactccct 2940
tgctgtcttt atggttttga tgtatgaaga atacactgoc taatttotaat gttaaaaagt 3000
cactgggtgc atgactagag cttaagtaag cactctgggg ttttcaaatg ttatattgtt 3060
ccataaatg gaaataaaca cctccataat aaaaaaaaaa aaaaaaaaaa a 3111

<211> 8
 <212> PRT
 <213> CHICKEN

<400> 3
 Ala Glu Val Gln Gly Gln Leu Pro
 1 5

<210> 4
 <211> 506
 <212> PRT
 <213> CHICKEN

<400> 4
 Glu Glu His Pro Glu Pro Ile Lys Ala Glu Val Gln Gly Gln Leu Pro
 1 5 10 15

Thr Trp Leu Gln Gly Val Leu Leu Arg Asn Gly Pro Gly Met His Thr
 20 25 30

Ile Gly Asp Thr Lys Tyr Asn His Trp Phe Asp Gly Leu Ala Leu Leu
 35 40 45

His Ser Phe Thr Phe Lys Asn Gly Glu Val Tyr Tyr Arg Ser Lys Tyr
 50 55 60

Leu Arg Ser Asp Thr Tyr Asn Cys Asn Ile Glu Ala Asn Arg Ile Val
 65 70 75 80

Val Ser Glu Phe Gly Thr Met Ala Tyr Pro Asp Pro Cys Lys Asn Ile
 85 90 95

Phe Ala Lys Ala Phe Ser Tyr Leu Ser His Thr Ile Pro Glu Phe Thr
 100 105 110

Asp Asn Cys Leu Ile Asn Ile Met Lys Thr Gly Asp Asp Tyr Tyr Ala
 115 120 125

Thr Ser Glu Thr Asn Phe Ile Arg Lys Ile Asp Pro Gln Thr Leu Glu
 130 135 140

Thr Leu Asp Lys Val Asp Tyr Ser Lys Tyr Val Ala Val Asn Leu Ala
 145 150 155 160

Thr Ser His Pro His Tyr Asp Ser Ala Gly Asn Ile Leu Asn Met Gly
 165 170 175

Thr Ser Ile Val Asp Lys Gly Arg Thr Lys Tyr Val Leu Phe Lys Ile
180 185 190

Pro Ser Ser Val Pro Glu Lys Glu Lys Lys Lys Ser Cys Phe Lys His
195 200 205

Leu Glu Val Val Cys Ser Ile Pro Ser Arg Ser Leu Leu Gln Pro Ser
210 215 220

Tyr Tyr His Ser Phe Gly Ile Thr Glu Asn Tyr Ile Val Phe Ile Glu
225 230 235 240

Gln Pro Phe Lys Leu Asp Ile Val Lys Leu Ala Thr Ala Tyr Ile Arg
245 250 255

Gly Val Asn Trp Ala Ser Cys Leu Ser Phe His Lys Glu Asp Lys Thr
260 265 270

Trp Phe His Phe Val Asp Arg Lys Thr Lys Lys Glu Val Ser Thr Lys
275 280 285

Phe Tyr Thr Asp Ala Leu Val Leu Tyr His His Ile Asn Ala Tyr Glu
290 295 300

Glu Asp Gly His Val Val Phe Asp Ile Val Ala Tyr Arg Asp Asn Ser
305 310 315 320

Leu Tyr Asp Met Phe Tyr Leu Lys Lys Leu Asp Lys Asp Phe Glu Val
325 330 335

Asn Asn Lys Leu Thr Ser Ile Pro Thr Cys Lys Arg Phe Val Val Pro
340 345 350

Leu Gln Tyr Asp Lys Asp Ala Glu Val Gly Ser Asn Leu Val Lys Leu
355 360 365

Pro Thr Ser Ala Thr Ala Val Lys Glu Lys Asp Gly Ser Ile Tyr Cys
370 375 380

Gln Pro Glu Ile Leu Cys Glu Gly Ile Glu Leu Pro Arg Val Asn Tyr
385 390 395 400

Asp Tyr Asn Gly Lys Lys Tyr Lys Tyr Val Tyr Ala Thr Glu Val Gln
405 410 415

Trp Ser Pro Val Pro Thr Lys Ile Ala Lys Leu Asn Val Gln Thr Lys
420 425 430

Glu Val Leu His Trp Gly Glu Asp His Cys Trp Pro Ser Glu Pro Ile
435 440 445

Phe Val Pro Ser Pro Asp Ala Arg Glu Glu Asp Glu Gly Val Val Leu
450 455 460

Thr Cys Val Val Val Ser Glu Pro Asn Lys Ala Pro Phe Leu Leu Ile
465 470 475 480

Leu Asp Ala Lys Thr Phe Lys Glu Leu Gly Arg Ala Thr Val Asn Val
485 490 495

Glu Met His Leu Asp Leu His Gly Met Phe
500 505

<210> 5

<211> 529

<212> PRT

<213> BOVINE

<400> 5

Glu Glu Leu Ser Ser Pro Leu Thr Ala His Val Thr Gly Arg Ile Pro
1 5 10 15

Leu Trp Leu Thr Gly Ser Leu Leu Arg Cys Phe Thr Gly Pro Gly Leu
20 25 30

Phe Glu Val Gly Ser Glu Pro Phe Tyr His Leu Phe Asp Gly Gln Ala
35 40 45

Leu Leu His Lys Phe Asp Phe Lys Glu Gly His Val Thr Tyr His Arg
50 55 60

Arg Phe Ile Arg Thr Asp Ala Tyr Val Arg Ala Met Thr Glu Lys Arg
65 70 75 80

Ile Val Ile Thr Glu Phe Gly Phe Thr Thr Cys Ala Phe Pro Asp Pro
85 90 95

Cys Lys Asn Ile Phe Ser Arg Phe Phe Ser Tyr Phe Arg Gly Val Glu
100 105 110

Val Thr Asp Asn Ala Leu Val Asn Val Tyr Pro Val Gly Glu Asp Tyr
115 120 125

Tyr Ala Cys Thr Glu Thr Asn Phe Ile Thr Lys Ile Asn Pro Glu Thr
130 135 140

Leu Glu Thr Ile Phe Thr Lys Gln Val Asp Leu Cys Asn Tyr Val Ser
145 150 155 160

Val Asn Gly Ala Thr Ala His Pro His Ile Glu Asn Asp Gly Thr Val
165 170 175

Tyr Asn Ile Gly Asn Cys Phe Gly Lys Asn Phe Ser Ile Ala Tyr Asn
180 185 190

Ile Val Lys Ile Pro Pro Leu Gln Ala Asp Lys Glu Asp Pro Ile Ser
195 200 205

Lys Phe Thr Ser Glu Ile Val Val Gln Phe Pro Cys Ser Asp Arg Phe
210 215 220

Lys Pro Ser Tyr Val His Ser Phe Gly Leu Thr Pro Asn Tyr Ile Val
225 230 235 240

Phe Val Glu Thr Pro Val Lys Ile Asn Leu Phe Lys Phe Leu Ser Ser
245 250 255

Trp Ser Leu Trp Gly Ala Asn Tyr Met Asp Cys Phe Glu Ser Phe Thr
260 265 270

Asn Glu Thr Met Gly Val Trp Leu His Ile Ala Asp Lys Lys Arg Lys
275 280 285

Lys Tyr Leu Asn Asn Lys Tyr Arg Thr Ser Pro Phe Asn Leu Phe His
290 295 300

His Ile Asn Thr Tyr Glu Asp Asn Gly Phe Leu Ile Val Asp Leu Cys
305 310 315 320

Cys Trp Lys Gly Phe Glu Phe Val Tyr Asn Tyr Phe Thr Leu Tyr Leu
325 330 335

Ala Asn Leu Arg Glu Asn Trp Glu Glu Val Lys Lys Asn Ala Arg Lys
340 345 350

Ala Pro Gln Pro Glu Val Arg Arg Tyr Val Leu Pro Leu Asn Ile Asp
355 360 365

Lys Ala Asp Thr Gly Lys Asn Leu Val Thr Leu Pro Asn Thr Thr Ala
370 375 380

Thr Ala Ile Leu Cys Ser Asp Glu Phe Thr Thr Ile Trp Leu Glu Pro
385 390 395 400

Glu Val Leu Phe Ser Gly Pro Arg Gln Ala Phe Glu Phe Pro Gln Ile
 405 410 415

Asn Tyr Gln Lys Tyr Cys Gly Lys Pro Tyr Thr Tyr Ala Tyr Gly Leu
 420 425 430

Gly Leu Asn His Phe Val Pro Asp Arg Leu Cys Lys Leu Asn Val Lys
 435 440 445

Thr Lys Glu Thr Trp Phe Thr Val Trp Gln Glu Pro Asp Ser Tyr Pro
 450 455 460

Ser Glu Pro Ile Phe Val Ser His Pro Asp Ala Leu Glu Glu Asp Asp
 465 470 475 480

Gly Val Val Leu Ser Val Val Val Ser Pro Gly Ala Gly Gln Lys Pro
 485 490 495

Ala Tyr Leu Leu Ile Leu Asn Ala Lys Asp Leu Ser Glu Val Ala Arg
 500 505 510

Ala Glu Phe Thr Val Glu Ile Asn Ile Pro Val Thr Phe His Gly Leu
 515 520 525

Phe

<210> 6

<211> 18

<212> PRT

<213> CHICKEN

<400> 6

Asn Lys Glu Glu His Pro Glu Pro Ile Lys Ala Glu Val Gln Gly Gln
 1 5 10 15

Leu Pro

<210> 7

<211> 18

<212> PRT

<213> CHICKEN

<400> 7

Asn Lys Glu Glu His Pro Glu Pro Ile Lys Ala Glu Val Gln Gly Gln
 1 5 10 15

Leu Pro

<210> 8
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Primer

<220>
 <221> modified_base
 <222> (18)
 <223> i

<400> 8
 aacaargarg ascaayccnga

20

<210> 9
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Primer

<220>
 <221> modified_base
 <222> (7)
 <223> i

<220>
 <221> modified_base
 <222> (13)
 <223> i

<400> 9
 sagctgnccc tgnacytcsg c

21

<210> 10
 <211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 10

tctgaattcc ggagcccata aaagc

25